🇺🇸 FDA
Pipeline program

SBRT combined with PD-1 inhibitors and thoracic hyperthermia

SBRT-PT

Phase 2 other active

Quick answer

SBRT combined with PD-1 inhibitors and thoracic hyperthermia for Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC is a Phase 2 program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC
Phase
Phase 2
Modality
other
Status
active

Clinical trials